Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fulgent GeneticsFLGT -1.90%64 ROC (Joel Greenblatt) % is -44.96% as of Mar. 2026. GuruFocus rates FLGT with a GF Score™ of 64/100 and a GF Value™ of $24.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 62.56% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Fulgent Genetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -44.96%.
The historical rank and industry rank for Fulgent Genetics's ROC (Joel Greenblatt) % or its related term are showing as below:
FLGT'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -180.59 Med: -20.6 Max: 511.14
Current: -45.45
During the past 12 years, Fulgent Genetics's highest ROC (Joel Greenblatt) % was 511.14%. The lowest was -180.59%. And the median was -20.60%.
FLGT's ROC (Joel Greenblatt) % is ranked worse than 62.56% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs FLGT: -45.45
Fulgent Genetics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Fulgent Genetics ROC (Joel Greenblatt) % Related Terms
Fulgent Genetics ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FLGT vs MYGN, CSTL, BDSX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -44.96% mean?
Fulgent Genetics (FLGT) has a ROC (Joel Greenblatt) % of -44.96% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Fulgent Genetics and its competitors. According to the industry distribution chart, Fulgent Genetics ranks #132 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 62.6%.
Is Fulgent Genetics' ROC (Joel Greenblatt) % too high?
Fulgent Genetics' current ROC (Joel Greenblatt) % is -44.96%. Based on the distribution chart, Fulgent Genetics ranks #132 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Fulgent Genetics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' ROC (Joel Greenblatt) % compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #132 out of 211 companies for ROC (Joel Greenblatt) %. This places Fulgent Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current ROC (Joel Greenblatt) % is -44.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.16, compared to a current price of $20.16 — trading 16.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is -44.96%. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current ROC (Joel Greenblatt) % is -44.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $20.16 is trading 16.6% below its estimated GF Value™ of $24.16.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
ROC (Joel Greenblatt) %: -44.96%
GF Value™: $24.16 vs. price of $20.16 (16.6% below fair value)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score
Get the complete analysis for FLGT
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
